PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community

PARP Inhibitors: Best Practices in Advanced Prostate Cancer Care in the Community

This educational series is supported by independent educational grants from AstraZeneca and Merck.

CME Available: https://auau.auanet.org/node/31224

Course Description: PARP Inhibitors: From Research to Practice, an exciting new educational initiative, is a series of three interactive, case-based, live virtual courses, featuring a unique topic related to PARP Inhibitors. For each session, a Moderator will engage two other subject matter experts in an interactive, interview-style presentation and discussion.

Based on the documented need from the 2019 AUA global needs assessment in advanced prostate cancer, the AUA has produced a new series of educational offerings for the urologic care team focused on PARP inhibitors (PARPi). The first of three in the series PARP Inhibitors: Assessing the Rapidly Evolving Treatment Landscape will address the latest developments in PARPi treatments and advanced prostate cancer care.

Upon completion of this activity, participants will be able to:
1. Describe the components of a multidisciplinary urologic cancer clinic and identify the best structure for the practice.
2. Identify opportunities for shared care and team-based approaches of patients with advanced prostate cancer.
3. Discuss the impact of shared-decision making on patient and on patient-clinician communication.
4. Describe how telemedicine can be successfully incorporated into the care continuum of patients with advanced prostate cancer.